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What is already known about this subject
• It was found that the genetic polymorphisms of CYP3A5,
CYP3A4 and MDR1 could affect the pharmacokinetics of
tacrolimus.
• This study was conducted to find such a possibility in the
Korean population.
What this study adds
• CYP3A5 polymorphisms are likely to be associated with
altered pharmacokinetics of tacrolimus in Koreans.
• MDR1 polymorphisms have no important role in the
pharmacokinetics of tacrolimus.
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Aims
To determine the frequencies of the genotypes of CYP3A5 and MDR1 and to examine
the influence of the polymorphisms of these genes on tacrolimus pharmacokinetics in
the Korean population.
Methods
Twenty-nine healthy Koreans who participated in the previous tacrolimus
pharmacokinetic study were genotyped for CYP3A4*1B, CYP3A5*3, MDR1
c.1236C→T, MDR1 c.2677G→A/T and MDR1 c.3435C→T. The relationship between
the genotypes so obtained and tacrolimus pharmacokinetics observed in the previous
study was examined.
Results
No subject in this study had the CYP3A4*1B variant. The observed frequencies of
CYP3A5*1/*1, *1/*3, and *3/*3 were 0.069 [confidence interval (CI) -0.023, 0.161],
0.483 (CI 0.301, 0.665) and 0.448 (CI 0.267, 0.629), respectively. AUC0–• for the
CYP3A5*1/*1 or *1/*3 genotype was 131.5  44.8 ng h ml-1 (CI 109.6, 153.5),
which was much lower compared with the CYP3A5*3/*3 genotype of
323.8  129.3 ng h ml-1 (CI 253.5, 394.1) (P = 2.063E-07). Similarly, Cmax for the
CYP3A5*1/*1 or *1/*3 genotype was 11.8  3.4 ng ml-1 (CI 10.1, 13.5), which was
also much lower compared with the CYP3A5*3/*3 genotype of 24.4  12.3 ng ml-1
(CI 17.8, 31.1) (P = 0.0001). However, there was no significant difference in
tacrolimus pharmacokinetics among the MDR1 diplotypes of CGC-CGC, CGC-TTT,
CGC-TGC, TTT-TGC or TTT-TTT (P = 0.2486).
Conclusions
This study shows that the CYP3A5*3 genetic polymorphisms may be associated with
the individual difference in tacrolimus pharmacokinetics. An individualized dosage
regimen design incorporating such genetic information would help increase clinical
efficacy of the drug while reducing adverse drug reactions.
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Introduction
Tacrolimus, one of the calcineurin inhibitors, is highly
effective in preventing acute rejection after transplanta-
tion of solid organs, including the liver and kidney [1].
However, tacrolimus shows high between- and within-
subject variability in pharmacokinetics, with a narrow
therapeutic index, necessitating therapeutic drug moni-
toring to optimize treatment [2–4].
It has become clear that the variability in the pharma-
cokinetics of tacrolimus is largely determined by differ-
ences in oral bioavailability [5]. Tacrolimus is a
substrate of P-glycoprotein, the product of the multidrug
resistance (MDR1) gene and has been known to undergo
extensive hepatic metabolism by cytochrome P450 3A4
(CYP3A4) and CYP3A5 [6–8]. The variability in oral
bioavailability of tacrolimus thus has been attributed
to individual differences in expression of CYP3A4,
CYP3A5 and P-glycoprotein [9].
A limited number of studies have reported on the
association between CYP3A4 variants and the pharma-
cokinetics of tacrolimus. Hesselink et al. found that
CYP3A4*1B carriers require larger dose of tacrolimus to
reach target trough concentrations compared with
CYP3A4*1 homozygotes [5]. In their work, it was estab-
lished that the dose requirement for tacrolimus could be
affected by CYP3A5 variants. Several studies have
reported that the dose-adjusted trough concentration of
tacrolimus is much higher in CYP3A5*3/*3 subjects
than in *1/*1 or *1/*3 subjects [10–15]. The CYP3A5*3
variant creates an alternative splice in pre-mRNA and
produces aberrant mRNA that does not translate into
functional CYP3A5 protein [16]. In contrast, numerous
studies have investigated whether the genetic polymor-
phisms in MDR1, including c.1236C→T, c.2677G→
A/T and c.3435C→T, could affect the pharmacokinetics
of tacrolimus, yielding controversial results [9].
In a previous pharmacokinetic study, we compared
the pharmacokinetics of twice-daily dosing of 1-mg tac-
rolimus capsules of two different formulations in
healthy Korean volunteers: Prograf (Astellas Pharma
Korea, Inc.), the reference, or conventional formulation,
and TacroBell® (Chong Kun Dang Pharmaceutical
Corp., Korea), the test, or newly developed formulation.
While no significant difference in formulation was
observed, we found high interindividual variability
[51–76%, coefficient of variation (CV)] in the pharma-
cokinetics of tacrolimus and suspected a possible
genetic polymorphism as a source of pharmacokinetic
variation [17]. In this regard, this study was intended to
see if such a possibility existed in the Korean popula-
tion. Subjects who had participated in the previous tac-
rolimus pharmacokinetic study were therefore first
examined for the frequencies of CYP3A4*1B,
CYP3A5*3 and three single nucleotide polymorphisms
(SNPs) of MDR1, c.1236C→T, c.2677G→A/T and
c.3435C→ T, and then for an association between the
resulting genotypes and tacrolimus pharmacokinetics
obtained in the previous study.
Materials and methods
Subjects
This study was approved by the institutional review
board of Yonsei University Medical Centre, Seoul,
Korea. A total of 29 unrelated healthy Korean volunteers
participated in this study after giving written informed
consent. They were recruited from the volunteers who
had participated in the previous pharmacokinetic study
of two oral formulations of tacrolimus [17].
Genetic analysis
We investigated the genotype frequencies of
CYP3A4*1B (GenBank accession number AC069294),
CYP3A5*3 (GenBank accession number AC005020)
and three SNPs of MDR1, c.1236C→T, c.2677G→A/T
and c.3435C→T (GenBank accession numbers
NC000007, NM000927) for the subjects by direct se-
quencing using an automated genetic analyser (Model
3700; Applied Biosystems, Foster City, CA, USA). The
nomenclature of CYP3A4 and CYP3A5 was based on the
website http://www.cypalleles.ki.se/. For each subject,
one blood sample was collected and DNA was extracted
using a purification kit (Qiagen, Hilden, Germany). Hap-
lotype assembly was performed using the Haploview 3.2
program (Broad Institute of Harvard and MIT, Cam-
bridge, MA, USA), based on a standard expectation-
maximization algorithm to reconstruct individual
haplotypes from population genotype data [18].
Pharmacokinetic data
For pharmacokinetic data, we used data obtained from
the previous pharmacokinetic study, which can be sum-
marized as follows [17]. It was as an open-label, ran-
domized, two-period, cross-over study with a 3-week
wash-out period in 29 healthy Korean volunteers. Each
subject received two 1-mg capsules of a conventional
(reference) or a newly developed (test) oral tacrolimus
formulation twice a day, morning and evening (total
daily dose of 4 mg). Blood samples were collected
before dosing and at 0.5, 1, 1.5, 2, 3, 4, 7, 12, 12.5, 13,
13.5, 14, 15, 16, 19, 24, 36, 48, 72 and 96 h after dosing.
Whole blood concentrations were analysed by LC/MS/
MS. Pharmacokinetic parameters such as area under the
concentration curve from time zero to infinity (AUC0–•),
maximum concentration (Cmax), time to Cmax (tmax) and
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half-life (t1/2) for tacrolimus were estimated by noncom-
partmental analysis using WinNonlin Professional 4.1.
In results, the two formulations were not significantly
different and showed similarly large interindividual
variation in tacrolimus pharmacokinetics [59.3–61.1%
(test) and 50.7–75.6% (reference) in CV]. Therefore, in
this study, without loss of generality, only the conven-
tional formulation’s pharmacokinetic data were used in
examining genetic influences on tacrolimus pharmaco-
kinetics.
Statistical analysis
Differences in pharmacokinetic parameters between the
genotype groups were tested using the Wilcoxon rank
sum test or the Kruskal–Wallis test. The frequency of
CYP3A5*3/*3 genotype was compared with that of the
other ethnic groups, using c2 test. P-values < 0.05 were
considered to be statistically significant.
Results
Polymorphisms of CYP3A5 and MDR1 in Koreans
Table 1 shows frequency distributions of CYP3A5 and
MDR1 genotypes in 29 Korean subjects examined in this
study. Each genotype did not deviate from Hardy–
Weinberg equilibrium. Among the CYP3A4*1B,
CYP3A5*3 and MDR1 genotypes examined in our study,
the CYP3A4*1B genotype was not observed in any
subject and the CYP3A5*1/*1 genotype was observed in
only two subjects, yielding a frequency of 0.069 [confi-
dence interval (CI) -0.023, 0.161), with CI indicating a
95% CI. In contrast, for the CYP3A5*3 variant, the het-
erozygous allele was observed in 14 subjects with a
frequency of 0.483 (CI 0.301, 0.665), while the homozy-
gous allele was observed in 13 subjects with a frequency
of 0.448 (CI 0.267, 0.629). The frequency of
CYP3A5*3/*3 observed with our subjects was similar to
that of 0.400 (CI 0.268, 0.532) with Chinese
(P = 0.5313) or 0.583 (CI 0.512, 0.654) with Japanese
(P = 0.1737) [19, 20]. However, some significant differ-
ences were also found in the frequency of this genotype.
That is, the frequency of CYP3A5*3/*3 genotype was
higher in Koreans compared with the frequency of 0.029
(CI -0.027, 0.085) in African-Americans (P = 0.0001),
but was much lower compared with the frequency of
0.830 (CI 0.756, 0.904) in Whites (P = 0.0001) [21,
22]. These results suggest that the frequency of
CYP3A5*3/*3 genotype is dependent on ethnicity.
The MDR1 haplotypes were estimated from the three
MDR1 genotypes at c.1236C→T, c.2677G→A/T and
c.3435C→T using a standard expectation-maximization
algorithm (Table 2). Three major haplotypes that were
relatively commonly observed were TTT, CGC and
TGC, accounting for 41.4%, 20.7% and 20.7% of the
total haplotype diversity, respectively. The combinations
of these three predominant haplotypes constituted the
five diplotypes examined in this study, CGC-CGC
(3.4%, n = 1), CGC-TTT (17.2%, n = 5), CGC-TGC
(10.3%, n = 3), TTT-TGC (31.0%, n = 9) and TTT-TTT
(10.3%, n = 3) (Table 3).
Pharmacokinetic parameters of tacrolimus
In this study, pharmacokinetic values were given as
mean SD with 95% CI. Table 4 shows that AUC0–• for
the subject with the CYP3A5*1/*1 or *1/*3 genotype
Table 1
Genotype frequencies for CYP3A5 and
MDR1 in healthy Koreans (n = 29)
Variant Genotype No. (frequency) 95% CI
CYP3A5*3 *1/*1 2 (0.069) (-0.023, 0.161)
*1/*3 14 (0.483) (0.301, 0.665)
*3/*3 13 (0.448) (0.267, 0.629)
MDR1 c.1236C→T CC 3 (0.103) (-0.008, 0.214)
CT 12 (0.414) (0.235, 0.593)
TT 14 (0.483) (0.301, 0.665)
MDR1 c.2677G→A/T GG 4 (0.138) (0.012, 0.264)
GA 2 (0.069) (-0.023, 0.161)
GT 15 (0.517) (0.335, 0.699)
AT 1 (0.034) (-0.032, 0.100)
AA 2 (0.069) (-0.023, 0.161)
TT 5 (0.172) (0.035, 0.309)
MDR1 c.3435C→T CC 8 (0.276) (0.113, 0.439)
CT 17 (0.586) (0.407, 0.765)
TT 4 (0.138) (0.012, 0.264)
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was 131.5 44.8 ng h ml-1 (CI 109.6, 153.5), which
was much lower compared with the CYP3A5*3/*3
genotype of 323.8 129.3 ng h ml-1 (CI 253.5, 394.1)
(P = 2.063E-07). Table 4 also shows that Cmax for the
subject with the CYP3A5*1/*1 or *1/*3 genotype was
11.8  3.4 ng ml-1 (CI 10.1, 13.5), which was also much
lower compared with the CYP3A5*3/*3 genotype of
24.4 12.3 ng ml-1 (CI 17.8, 31.1) (P = 0.0001). The
Table 2
Haplotype frequencies of
MDR1 c.1236C→T, c.2677G→A/T,
c.3435C→T in healthy Koreans (n = 29)
Haplotype c.1236C,T c.2677G,A/T c.3435C,T Frequency (95% CI)
TTT T T T 0.414 (0.287, 0.541)
CGC C G C 0.207 (0.103, 0.311)
TGC T G C 0.207 (0.103, 0.311)
CAC C A C 0.069 (0.004, 0.134)
TAC T A C 0.034 (-0.013, 0.081)
TTC T T C 0.034 (-0.013, 0.081)
CGT C G T 0.017 (-0.016, 0.050)
Table 3
Tacrolimus pharmacokinetic parameters
against major MDR1 genotypes in
healthy Koreans (n = 21)
Diplotype
(no.)
AUC0–•
(ng h ml-1)
Cmax
(ng ml-1)
tmax
(h)
t1/2
(h)
CGC-CGC 565.7 30.9 2.0 31.2
(1)
CGC-TTT 138.1 38.9 11.7 3.5 1.2 0.3 23.3 12.6
(5) (104.0, 172.2) (8.6, 14.8) (1.0, 1.4) (12.3, 34.4)
CGC-TGC 233.0 106.0 18.3 4.4 1.7 0.3 23.4 3.1
(3) (113.1, 353.0) (13.3, 23.3) (1.3, 2.0) (19.9, 26.9)
TTT-TGC 250.9 157.8 19.0 13.4 1.6 0.9 31.6 12.0
(9) (147.9, 354.0) (10.3, 27.7) (1.0, 2.2) (23.8, 39.4)
TTT-TTT 200.3 69.2 16.3 5.6 1.3 0.3 33.9 11.4
(3) (122.0, 278.6) (9.9, 22.6) (1.0, 1.7) (21.0, 46.9)
P-value* 0.2486 0.3926 0.4733 0.4609
Values are given as mean  SD. Values in parentheses represent the 95%
confidence interval. *Kruskal–Wallis test.
Table 4
Tacrolimus pharmacokinetic parameters
vs. CYP3A5 genotypes in healthy Koreans
(n = 29)
Genotype
AUC0–•
(ng h ml-1)
Cmax
(ng ml-1)
tmax
(h)
t1/2
(h)
CYP3A5 131.5 44.8 11.8 3.4 1.4 0.7 23.9 11.9
*1/*1 or *1/*3 (109.6, 153.5) (10.1, 13.5) (1.1, 1.7) (18.0, 29.7)
CYP3A5 323.8 129.3 24.4 12.3 1.6 0.4 30.6 8.7
*3/*3 (253.5, 394.1) (17.8, 31.1) (1.4, 1.8) (25.9, 35.3)
P-value* 2.0630E-07 0.0001 0.1160 0.1103
Values are given as mean  SD. Values in parentheses represent the 95%
confidence interval. *Wilcoxon rank sum test.
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values of tmax and t1/2 were similar between the two geno-
type groups (P = 0.1160, 0.1103, respectively). The
genotype differences in AUC0–• and Cmax of tacrolimus
are visually depicted in Figure 1.
There was no significant difference in pharmacokinet-
ics of tacrolimus among the five MDR1 diplotype groups
(P = 0.2486) (Table 3).
Discussion
In the present study, we observed a significant association
between the blood concentration of tacrolimus and the
CYP3A5*3 variant. Our results show that subjects with
the CYP3A5*1/*1 or *1/*3 genotype yield much lower
AUC0–• and Cmax values than the CYP3A5*3/*3 geno-
type. To investigate other possibilities that may contribute
to such pharmacokinetic differences, demographic
factors including age, sex, height and body weight were
compared between the two genotype groups. No demo-
graphic factor showed a significant difference between
the two groups other than age, which showed distribu-
tions (mean  SD) of 31.4 8.3 years for the
CYP3A5*1/*1 or *1/*3 genotype vs. 25.6 2.1 years
for the CYP3A5*3/*3 genotype (P = 0.0153) (Table 5).
However, it has been reported that CYP3A activity is not
significantly influenced by age [23].
Several studies have reported the interethnic variation
in the pharmacokinetics of tacrolimus [24, 25]. In rela-
tion to interethnic differences in the frequency of the
CYP3A5*3 allele, Thompson et al. found that the fre-
quency is lowest in sub-Saharan Africa and highest in
European and East Asian populations, showing an
increasing trend with distance from the equator [26].
Similarly in this work, we found that the CYP3A5*3/*3
genotype was more common in Koreans and Whites
than in African-Americans. The interethnic difference in
the frequency of CYP3A5*3/*3 genotype may contribute
to the interethnic variation in the pharmacokinetics of
tacrolimus.
In our subjects, no one had the CYP3A4*1B variant.
According to the work by Lamba et al., this genotype
was not found in Japanese-Americans or in Chinese-
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Figure 1
AUC0–• (A) and Cmax (B) of tacrolimus illustrated according to the
CYP3A5 genotype. Triangles, CYP3A5*1/*1 or *1/*3 (n = 16); circles,
CYP3A5*3/*3 (n = 13). A thick bar indicates the mean value of the group
Table 5
Demographic characteristics of the
CYP3A5 genotype in healthy Koreans
(n = 29)
Genotype
Sex
(male:female)
Age*
(years)
Weight*
(kg)
Height*
(cm)
CYP3A5 12 : 4 31.4 8.3 64.4 9.0 170.5 5.4
*1/*1 or *1/*3 (20–51) (48–78) (160–182)
CYP3A5 10 : 3 25.6 2.1 68.7 11.1 172.2 8.5
*3/*3 (23–30) (48–87) (155–181)
P-value >0.9999† 0.0153‡ 0.2760‡ 0.5314‡
*Values are given as mean  SD. Values in parentheses represent the range.
†Fisher’s exact test. ‡t-test.
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Americans, while frequencies of 2.0–9.6% and 35–67%
were observed in Whites and African-Americans,
respectively [16]. These findings indicate that the fre-
quency of the CYP3A4*1B allele may vary among ethnic
groups.
In our results, no significant difference was found in
tacrolimus pharmacokinetics against MDR1 polymor-
phisms in c.1236C→T, c.2677G→A/T or c.3435C→T,
indicating a nonsignificant association between the blood
concentration of tacrolimus and these three genotype
groups (data not shown). Although many researchers
have tried to examine whether these three SNPs could
affect the expression and function of MDR1, the results
are still controversial [27]. Recently, it has been con-
firmed that MDR1 c.3435C→T is in significant linkage
disequilibrium with c.1236C→T and c.2677G→A/T and
the analysis of MDR1 haplotypes may be superior to that
of SNPs in revealing genotype–phenotype associations in
pharmacokinetic studies [8, 27–29].
In our work, we estimated the MDR1 haplotypes
from the three MDR1 genotypes at c.1236C→T,
c.2677G→A/T and c.3435C→T using a standard
expectation-maximization algorithm. Three predomi-
nant haplotypes were observed and the combinations of
these three haplotypes constituted the five diplotypes,
with no significant difference observed in tacrolimus
pharmacokinetics among these five MDR1 diplotypes.
Thus, although it was found that the subject with CGC-
CGC diplotype showed much higher AUC0–• and Cmax
compared with the other subjects (Table 3), this may be
mainly due to the influence of the CYP3A5*3/*3 geno-
type of this subject (Table 4).
In conclusion, our study demonstrates that the
CYP3A5 genetic polymorphisms may be associated with
the pharmacokinetic variation of tacrolimus in Korean
populations. Therefore, dosage regimen design incorpo-
rating genetic polymorphisms in CYP3A5 may be of
help in identifying the optimal dose for the individual
patient.
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